Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study)

Am J Cardiol. 2003 Aug 1;92(3):305-8. doi: 10.1016/s0002-9149(03)00633-7.

Abstract

This report provides preliminary evidence that statins may lower C-reactive protein levels by interfering with the generation and/or release of C-reactive protein in the liver rather than by modulating inflammatory processes in the vessel wall.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Biomarkers / blood
  • Blood Glucose / drug effects
  • Blood Pressure / drug effects
  • C-Reactive Protein / drug effects*
  • Coronary Disease / blood*
  • Coronary Disease / complications
  • Coronary Disease / drug therapy*
  • Diabetes Complications
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hypertension / complications
  • Inflammation / blood
  • Inflammation / drug therapy
  • Interleukin-6 / blood*
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Biomarkers
  • Blood Glucose
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Interleukin-6
  • C-Reactive Protein